ProCE Banner Activity

Understanding the Interdependencies of Targeted Pathways: Rationale for PARP Inhibitor Combinations

Slideset Download
Download these slides from a live Webinar to learn about the rationale underlying PARP inhibitor combination therapeutic strategies in metastatic castration-resistant prostate cancer.

Released: June 15, 2021

Expiration: June 14, 2022

No longer available for credit.

Share

Faculty

Joaquin Mateo

Joaquin Mateo, MD, PhD

Group Leader
Prostate Cancer Translational Research
Vall d Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d Hebron University Hospital
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Joaquin Mateo, MD, PhD

Group Leader
Prostate Cancer Translational Research
Vall d Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d Hebron University Hospital
Barcelona, Spain